Diary - News All news Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

Recent developments include:
• Assembling a diverse portfolio of therapeutic peptides targeting clinical indications with high unmet need
• Launching collaborations with prestigious US academic groups
• Strengthening the leadership team

Lyon, France, November 14, 2018 - Alizé Pharma 3, a company specialized in developing therapeutic peptides for the treatment of rare endocrine and
metabolic diseases, today announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading
global rare disease company.